Novartis has deepened its collaboration with Monte Rosa Therapeutics by securing exclusive rights and options on molecular glue degraders for immune-mediated diseases in a deal valued at up to $5.7 billion. This marks Novartis' second agreement with Monte Rosa within eleven months, underscoring its commitment to targeted protein degradation technologies. Monte Rosa will conduct early-stage discovery and testing, while Novartis will handle later development stages. The upfront payment totals $120 million, with potential milestones and royalties adding significantly. This partnership capitalizes on Monte Rosa’s QuEEN platform aimed at diseases with high unmet need.